Karyopharm Therapeutics Inc. Share Price
Equities
KPTI
US48576U1060
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | 0.00% | -9.40% | +22.54% |
Sales 2024 * | 147M 11.73B | Sales 2025 * | 165M 13.19B | Capitalization | 123M 9.88B |
---|---|---|---|---|---|
Net income 2024 * | -146M -11.69B | Net income 2025 * | -182M -14.57B | EV / Sales 2024 * | 1.35 x |
Net Debt 2024 * | 74M 5.92B | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.75 x |
P/E ratio 2024 * |
-0.87
x | P/E ratio 2025 * |
-1.01
x | Employees | 325 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.59% |
Latest transcript on Karyopharm Therapeutics Inc.
1 week | -9.40% | ||
Current month | -29.80% | ||
1 month | -28.38% | ||
3 months | +16.98% | ||
6 months | +28.59% | ||
Current year | +22.54% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 56 | 25/02/20 |
Mike Mason
DFI | Director of Finance/CFO | 49 | 24/02/19 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 02/10/13 |
Barry Greene
BRD | Director/Board Member | 60 | 31/12/12 |
Director/Board Member | 59 | 31/03/13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.06 | 0.00% | 660,736 |
25/04/24 | 1.06 | -2.75% | 644,718 |
24/04/24 | 1.09 | 0.00% | 1,204,243 |
23/04/24 | 1.09 | -3.54% | 1,591,093 |
22/04/24 | 1.13 | -3.42% | 791,015 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.54% | 123M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KPTI Stock